Daniel Horber

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Dieter Koeberle, Jean‐François Dufour, Gyula Demeter et al. · Annals of Oncology · 2016 · 139 citations · Full text

Medicine, Oncology, Pharmacology +15

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Dirk Kienle, Daniel Dietrich, Karin Ribi et al. · Journal of Geriatric Oncology · 2018 · 28 citations

Medicine, Oncology, Pharmacology +10

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-?-d-arabinofuranosylcytosine

Reto A. Schwendener, Daniel Horber, B Odermatt et al. · Journal of Cancer Research and Clinical Oncology · 1996 · 24 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +11

Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N 4 -alkyl-1-β- D -arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′ → 5′)- N 4 -octadecyl-1-β- d -arabinofuranosylcytosine

Daniel Horber, Rosanna M. C. Cattaneo-Pangrazzi, Prisca von Ballmoos et al. · Journal of Cancer Research and Clinical Oncology · 2000 · 20 citations · Full text

Life Sciences, Biochemistry, Oncology +13

Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients

Ignazio Tarantino, Philipp Achermann, Ulrich Güller et al. · Annals of Surgical Oncology · 2013 · 19 citations · Full text

Medicine, Oncology, Cancer Epidemiology +14